messag report top bottom line beat driven larg
biktarvi letairi co also bump top line guidanc slightli
said focu call remain larg pipelin overal continu
see valu base busi late stage pipelin cash posit think
recent event glpg sever smaller technolog in-licens deal sign
build momentum behind busi develop bd engin maintain buy
rais pt
call takeaway follow co recent glpg deal thought ceo day
re-emphas deal begin continu focus bolster
co later stage pipelin also build innov network help fuel earli
stage asset beyond bd discuss prep also key topic convers given
encourag trend commerci plu upcom adcom descovi co
anticip us approv highlight signific enthusiasm descovi prep
recent post ia kol call takeaway filgotinib file track
respons one drug price call note exposur part
low doubl digit rang work on-going help shape ultim outcom
page analyst certif import disclosur
compani report factset
compani report factset
updat model reflect result glpg deal feedback
ia kol call increas descovi prep share estim prev
back increas convict follow ia kol call adjust opex
glpg deal arrang increas filgotinib estim million
million sale increas po filgotinib due anticip
us regulatori submiss ad estim po
net result chang increas pt
page analyst certif import disclosur
page analyst certif import disclosur
price target per share prev base dcf analysi forecast probability-weight revenu
expens assum discount rate termin growth rate
suscept risk appli entir biotech industri includ develop regulatori commerci manufactur
financ ip risk specif includ
commerci risk possibl may fail introduc new product market current product could produc less revenu
expect patient identif may slower expect product may receiv unfavor payor reimburs
clinic risk sever key pipelin product still clinic develop may delay clinic trial initi enrol
unexpect safeti issu efficaci lower expect
regulatori risk clinic trial ultim success possibl gild medicin approv global regulatori
agenc agenc may requir addit long-term data could delay potenti approv
ip risk depend intellectu properti protect control trade secret technolog innov inabl
defend patent could result increas gener competit addit compani may accus infring ip
current sever legal proceed relat product
competitor risk hiv hcv busi repres signific amount total product sale mix could face increas
competit aggress competit face signific competit therapi develop includ liver diseas
inflamm oncolog multipl compani develop therapi could prove better safeti efficaci
move faster market
page analyst certif import disclosur
mm except per share data
royalti contract revenu
factset consensu
total incom expens net
incom tax
net loss attribut non-controlling interest
net incom attribut
cog
sg
pre-tax adjustmentstax
non-gaap net incom attribut
factset consensu
cog tot prod sale
 tot revenu
sg tot revenu
compani report guggenheim secur llc estim
page analyst certif import disclosur
